HEALING HORIZONS IN ACID REFLUX DISEASE:
THE MANIFESTATIONS AND MEDICAL MANAGEMENT OF GERD

Supplement 5 to Volume 70, November 2003

SUPPLEMENT EDITOR
JOEL E. RICHTER, MD
The Cleveland Clinic

Contents and Faculty

GERD pathogenesis, pathophysiology, and clinical manifestations S4

PETER J. KAHRILAS, MD
Chief, Division of Gastroenterology and Hepatology, and Gilbert H. Marquardt Professor of Medicine, Northwestern University Medical School, Chicago, Ill.

Extraesophageal symptoms of GERD S20

KENNETH R. DEVAULT, MD
Associate Professor of Medicine, Mayo School of Medicine, and Director of Gastrointestinal Research, Mayo Clinic, Jacksonville, Fla.

The continuum of GERD complications S33

M. BRIAN FENNERTY, MD
Professor of Medicine and Section Chief, Gastroenterology, Oregon Health and Science University, Portland, Ore.

Profile and assessment of GERD pharmacotherapy S51

PAUL N. MATON, MD
Digestive Diseases Research Institute, Oklahoma City, Okla.

This supplement was supported by an educational grant from AstraZeneca LP.

This supplement was adapted from selected chapters of the *GI Masters Program: Healing Horizons in Acid Reflux Disease, Home Study Book*, 2nd edition, edited by Joel E. Richter, MD, ©2003 by The Cleveland Clinic Foundation.

Disclosures

The following authors and editor reported that they may have a relationship that, in the context of their contributions to this supplement, could be perceived as a potential conflict of interest:

Kenneth R. DeVault, MD, reported that he has received grant/research support from AstraZeneca Pharmaceuticals, Janssen Pharmaceutica, and Medtronic.

Peter J. Kahrilas, MD, reported that he has received grant/research support from, serves as a consultant to, and is on the speakers' bureaus of AstraZeneca Pharmaceuticals and Janssen Pharmaceutica. He also reported that he is a consultant to Medtronic and is on the speakers' bureaus of TAP Pharmaceutical Products and Wyeth Pharmaceuticals.

Paul N. Maton, MD, reported that he serves as a consultant to AstraZeneca Pharmaceuticals and Wyeth Pharmaceuticals.

Joel E. Richter, MD, reported that he serves as a consultant to AstraZeneca Pharmaceuticals and is on the speakers' bureaus of AstraZeneca Pharmaceuticals, Janssen Pharmaceutica, Medtronic, TAP Pharmaceutical Products, and Wyeth Pharmaceuticals.

M. Brian Fennerty, MD, reported that he has no relationships that, in the context of his contribution, could be perceived as a potential conflict of interest.

Copyright© 2003 The Cleveland Clinic Foundation.

The statements and opinions expressed in this supplement to the *Cleveland Clinic Journal of Medicine* are those of the authors and not necessarily of The Cleveland Clinic Foundation, its Board of Trustees, or AstraZeneca LP.

The *Cleveland Clinic Journal of Medicine* (ISSN 0891-1150) is published 12 times yearly by The Cleveland Clinic Foundation.

Subscription rates: U.S. and possessions: personal $98; institutional $124; single copy/back issue $16. Foreign: $124; single copy/back issue $16. Institutional (multiple-reader rate) applies to libraries, schools, hospitals, and federal, commercial, and private institutions and organizations. Individual subscriptions must be in the names of, billed to, and paid by individuals.

Postmaster address changes: Cleveland Clinic Journal of Medicine, NA32, 9500 Euclid Avenue, Cleveland, OH 44195. Subscription orders, editorial, reprint, and production offices (same address): (216) 444-2661 (phone); (216) 444-9385 (fax); ccjm@ccf.org (e-mail); www.ccjm.org (Web).

Printed in USA.